Skip to content
Screener

Harrow HROW Investing Cash Flow

Investing Cash Flow at other companies

AbbVie logo
AbbVieABBV
-$574M+21.9%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
-$15.08M
Bausch + Lomb logo
Bausch + LombBLCO
-$87M+3.3%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$4.66M-141%
Opko Health logo
Opko HealthOPK
$15.54M
Bausch Health Companies logo
Bausch Health CompaniesBHC
-$139M-6.9%

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total equity$28.7M-49.1%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.49B+22.8%
Enterprise value$1.7B+5.6%
P/S5.5×+0.2×

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Harrow’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:31 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001493152-26-022254
Line item2026 / For the Three Months Ended March 31,2025 / For the Three Months Ended March 31,
Investment in patent and trademark assets(9,000)(42,000)
Purchase of product rights(18,000,000)-
Purchases of property, plant and equipment(194,000)(170,000)
NET CASH USED IN INVESTING ACTIVITIES(18,203,000)(212,000)
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from 8.625% notes payable, net of commissions49,000,000-
Payment of debt issuance costs(113,000)-
Proceeds from exercise of stock options25,00023,000

Item 1. Financial Statements (unaudited) Item

FAQ

What is Harrow's investing cash flow?
Harrow (HROW) reported investing cash flow of -$18.2M in Q1 2026.
How has Harrow's investing cash flow changed year-over-year?
Harrow's investing cash flow decreased by 8486.3% year-over-year, from -$212K to -$18.2M.
What is the long-term trend for Harrow's investing cash flow?
Over 4 years (2021 to 2025), Harrow's investing cash flow has grown at a -26.5% compound annual growth rate (CAGR), from -$18.69M to -$5.46M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Harrow's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude